Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MTX Discontinuation on Shingrix Response in RA
NCT06574594Recruiting
- Sponsor
- Konkuk University Medical Center
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by Konkuk University Medical Center. Primary endpoint: Cell-mediated immunity (CD4+ and CD8+ T cell against herpes zoster). Started Aug 2024; status: recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06574594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574594.